Literature DB >> 24255776

Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study.

Kun Xiao1, Long-Xiang Su, Bing-Chao Han, Peng Yan, Na Yuan, Jie Deng, Jia Li, Li-Xin Xie.   

Abstract

BACKGROUND: Community-acquired pneumonia (CAP) is a prevalent and potentially life-threatening infection, and has poor prognosis in aged patients. The objective of this study was to compare the potential of admission N-terminal pro B-type natriuretic peptide (proBNP) levels and scoring models [CURB-65, Pneumonia Severity Index (PSI), and Acute Physiology and Chronic Health Evaluation (APACHE) II scores] to predict outcomes for aged patients with CAP admitted to Intensive Care Unit (ICU), and to explore the prognostic factors.
METHODS: Clinical data of the patients were collected retrospectively, whose CURB-65, PSI, APACHE II scores were calculated and in whom measurements of proBNP was performed. The outcomes of interest were severity evaluation, prediction of need for mechanical ventilation and 28-day mortality. Receiver operating characteristic (ROC) curve was conducted to predict the assessment ability of proBNP and scoring models on different outcomes, and the logistic regression analysis was performed to screen factors affecting prognosis.
RESULTS: 240 patients were enrolled, with the mean age of 75±8 years old. Admission levels of NT-proBNP, scoring models were significantly higher in SCAP patients, MV group, and non-survivors compared to non-SCAP patients, no-MV group, and 28-day survivors, respectively (P<0.001). PSI had the highest area under the curve (AUC) and specificity for the three outcomes considered (AUC: 0.868 and specificity: 0.906 for 28-day mortality, AUC: 0.864 and specificity: 0.831 for requirement of MV, and AUC: 0.888 and specificity: 0.894 for severity evaluation). NT-proBNP had the highest sensitivity of 0.987 and 0.903 on prediction of mortality and need for MV. And APACHE II scoring model with the highest sensitivity of 0.890 was used to evaluate severity. Logistic regression analysis showed that the odd ratio (OR) of systolic blood pressure, PSI, and APACHE II scores were 0.886, 1.019, and 1.249.
CONCLUSIONS: PSI scores was the best indicator in predicting different clinical outcomes of aged patients with CAP among the proBNP and three scoring systems. Systolic blood pressure might be as a protective factor for prognosis while PSI and APACHE II scores as risk factors for prognosis of aged patients with CAP.

Entities:  

Keywords:  Aged; community-acquired pneumonia (CAP); prognosis; severity

Year:  2013        PMID: 24255776      PMCID: PMC3815733          DOI: 10.3978/j.issn.2072-1439.2013.09.10

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  29 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 2.  Severe community-acquired pneumonia.

Authors:  Francisco Alvarez-Lerma; Antoni Torres
Journal:  Curr Opin Crit Care       Date:  2004-10       Impact factor: 3.687

Review 3.  Actual causes of death in the United States, 2000.

Authors:  Ali H Mokdad; James S Marks; Donna F Stroup; Julie L Gerberding
Journal:  JAMA       Date:  2004-03-10       Impact factor: 56.272

4.  Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia.

Authors:  Ki Young Jeong; Kyuseok Kim; Tae Yun Kim; Christopher C Lee; Si On Jo; Joong Eui Rhee; You Hwan Jo; Gil Joon Suh; Adam J Singer
Journal:  Emerg Med J       Date:  2010-05-29       Impact factor: 2.740

5.  Development and validation of a clinical prediction rule for severe community-acquired pneumonia.

Authors:  Pedro P España; Alberto Capelastegui; Inmaculada Gorordo; Cristobal Esteban; Mikel Oribe; Miguel Ortega; Amaia Bilbao; José M Quintana
Journal:  Am J Respir Crit Care Med       Date:  2006-09-14       Impact factor: 21.405

6.  Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia.

Authors:  J D Chalmers; A Singanayagam; A T Hill
Journal:  Thorax       Date:  2008-05-20       Impact factor: 9.139

7.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

Authors:  B J Marston; J F Plouffe; T M File; B A Hackman; S J Salstrom; H B Lipman; M S Kolczak; R F Breiman
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

8.  Community-acquired pneumonia in adults.

Authors:  Julio A Ramirez
Journal:  Prim Care       Date:  2003-03       Impact factor: 2.907

9.  Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.

Authors:  Peter M Houck; Dale W Bratzler; Wato Nsa; Allen Ma; John G Bartlett
Journal:  Arch Intern Med       Date:  2004-03-22

10.  Comparison of severity predictive rules for hospitalised nursing home-acquired pneumonia in Korea: a retrospective observational study.

Authors:  Jong-Chan Lee; Hee-Jin Hwang; Yo-Han Park; Jun-Hyeon Joe; Jae-Ho Chung; Sang-Hwan Kim
Journal:  Prim Care Respir J       Date:  2013-06
View more
  3 in total

1.  IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients.

Authors:  M R Bacci; R C P Leme; N P C Zing; N Murad; F Adami; P F Hinnig; D Feder; A C P Chagas; F L A Fonseca
Journal:  Braz J Med Biol Res       Date:  2015-02-24       Impact factor: 2.590

2.  Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia.

Authors:  Ilija Andrijevic; Jovan Matijasevic; Ljiljana Andrijevic; Tomi Kovacevic; Bojan Zaric
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

3.  The mortality risk factor of community acquired pneumonia patients with chronic obstructive pulmonary disease: a retrospective cohort study.

Authors:  Ruo-Xuan Dai; Qing-Hua Kong; Bei Mao; Wen Xu; Ru-Jia Tao; Xiao-Ru Wang; Qing-Yao Kong; Jin-Fu Xu
Journal:  BMC Pulm Med       Date:  2018-01-22       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.